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Purpose
Comparison of variant frequencies in the general population has become an essential part
of the American College of Medical Genetics and Genomics (ACMG) standards and guide-
lines for interpreting sequence variants. We determined the optimal number of relevant
ethnic controls that should be used to accurately calculate the odds ratio (OR) of genetic
variants. 
Materials and Methods
Using the ACMG guidelines, we reclassified BRCA1 and BRCA2 mutations and variants of
unknown significance in 745 Korean patients susceptible to hereditary breast and ovarian
cancer compared with 1,314 Korean population controls.  
Results
We observed that the ORs were falsely inflated when we analyzed several variants using
non-Korean population data. Our simulation indicated that the number of controls needed
for the lower limit of a 95% confidence interval to exceed 1.0 varied according to the fre-
quency of the variant in each patient group, with more than 820 controls needed for a vari-
ant existing in 1% of cases. Using a sufficient number of relevant population data, we could
efficiently classify variants and identified the BRCA1 p.Leu1780Pro mutation as a possible
pathogenic founder mutation in Korean patients.
Conclusion
Our study suggests that BRCA1 p.Leu1780Pro is a novel pathogenic mutation found in 
Korean patients. We also determined the optimal number of relevant ethnic controls needed
for accurate variant classification according to the ACMG guidelines.
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Introduction
Genetic and genomic tests are rapidly expanding, and the
interpretation of genetic variants is a great challenge now
that many genetic variants of unknown significance (VUS)
have been identified. Among those genes for which variant
interpretation is challenging, BRCA1 and BRCA2 are of par-
ticular interest because of the significant clinical implications
of pathogenic mutations and the high prevalence of missense
VUS that complicate clinical diagnoses and decisions [1].
Germline mutations in BRCA1 or BRCA2 are clinically cor-
related with hereditary breast and ovarian cancer (HBOC)
syndrome, which features early-onset breast cancer, a high
incidence of ovarian cancer, and an increased risk of other
cancers, including prostate and pancreatic cancers [2].
BRCA1/2 testing is now an essential part of the management
of HBOC syndrome, but in practice, approximately 5%-21%
of patients tested for BRCA1/2 have one or more VUS, with
Asians and African Americans having higher rates [3-7]. 
Although several public databases, including the Breast Can-
cer Information Core (BIC, http://research.nhgri.nih.gov/
bic/) and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/),
provide estimated risks for certain VUS, interpretation of
VUS in Asian populations is still problematic due to limited
data. 
In response to the need for standardized and intercommu-
nicable assessment, the American College of Medical Genet-
ics and Genomics (ACMG) recently established standards
and guidelines for the interpretation of sequence variants [8].
The standards and guidelines suggest a 5-tier variant classi-
fication with the following categories: pathogenic (P), likely
pathogenic (LP), VUS, likely benign (LB), and benign (B).
These classifications are determined by incorporating evi-
dence from population, computational, functional, familial
segregation, de novo, allelic, and database data. Nevertheless,
there may still be issues of ambiguity and subjectivity in
some analyses; therefore, applying objective criteria will be
important to increasing reliability and reducing the uncer-
tainty associated with the interpretation. Comparing variant
frequencies in the general population is a good example of
such an objective measure that has become an essential part
of the ACMG guidelines. The ACMG recommends that the
odds ratio (OR) be calculated based on the occurrence of the
variant in cases and in the general population. Additionally,
the lower limit of a 95% confidence interval (CI) of an OR
that exceeds 1.0 should be regarded as strong evidence of
pathogenicity (PS4) [8]. However, there is still debate regard-
ing which population data should be used for OR calcula-
tions.
Recent studies have attempted to reclassify variants 
according to the ACMG guidelines [9-12]; however, the pro-
portion of VUS is still high, particularly in patients from eth-
nic groups for which there is insufficient genetic and ge-
nomic information [12]. Here, we evaluated BRCA1/2
variants in Korean patients suspected of having HBOC ac-
cording to the ACMG guidelines. Our simulation demon-
strated that the optimal number of accurate ethnic controls
was needed for rare pathogenic variants to be properly
scored by this statistical approach. 
Materials and Methods
1. Subjects 
This study included 745 women with at least one clinical
feature of HBOC who were evaluated for BRCA1/2 germline
mutational status at Yonsei Cancer Center between January
2008 and January 2016. The clinical features of HBOC 
included (1) at least one first- or second-degree relative with
breast and/or ovarian cancer, (2) breast cancer diagnosed 
before age 40, (3) bilateral breast cancer, (4) breast cancer and
synchronous or metachronous ovarian cancer, and (5) epithe-
lial ovarian cancer. We observed breast tumors in 596 
patients, ovary tumors in 124 patients, and both breast and
ovary tumors in 25 patients. The World Medical Association
Declaration of Helsinki on medical research protocols and
ethics was followed throughout the study. The institutional
review board reviewed and approved this study.
2. BRCA1 and BRCA2 testing and variant analysis
After extraction of patient genomic DNA from peripheral
blood, the entire coding regions and exon-intron boundaries
(±20 base pairs) of the BRCA1 and BRCA2 genes were ana-
lyzed by Sanger sequencing. Reference sequences used for
analysis were NM_007294.3 for BRCA1 and NM_000059.3 for
BRCA2. Variant descriptions followed the nomenclature sys-
tem of the Human Genome Variation Society (http://www.
hgvs.org/mutnomen). Variants were originally reported by
a 3-tier system, and those reported as disease-causing muta-
tions or VUS were further evaluated and reclassified accord-
ing to the ACMG guidelines as described below. 
3. Statistical analysis using population control data
Various population data were used for the statistical analy-
sis of each variant. From the Exome Aggregation Consortium
(ExAC), allele frequencies in 52,758 individuals, excluding
those who belong to the Cancer Genome Atlas consortium,
were retrieved. For each variant site, genotype data passing
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the quality cutoffs as defined by the ExAC were analyzed.
The ExAC populations used for final analysis included: 4,533
African/African American (AFR), 5,608 Latino (AMR), 3,933
East Asian (EAS), 3,307 Finnish, 27,173 Non-Finnish Euro-
pean (NFE), and 8,204 South Asian individuals. We also 
retrieved allele frequencies from 1,314 Koreans, including
622 individuals from the Korean Reference Genome DB
(KRGDB, http://152.99.75.168/KRGDB/) and 692 individu-
als from the database of a commercial laboratory, the Thera-
gen Etex Bio Institute (Suwon, Korea). For each variant, the
OR was calculated based on its occurrence in 745 patient
cases and in population controls described above. For those
variants that were not present in the population controls, the
corrected OR was calculated by adding 0.5 to all cells in a 22
table, as previously described [13].
4. Other assessments for ACMG classification
Computational predictions for missense variations were
calculated using the SIFT, PolyPhen-2, MutationTaster, 
MutationAssessor, and FATHMM algorithms [14]. Patho-
genic or benign evidence was scored when predictions of all
algorithms agreed. GVGD prior probability was also 
retrieved (http://agvgd.iarc.fr/) for comparison. Splice site
analysis was determined using the SpliceFinder-like, Max-
EntScan, NNSPLICE, GeneSplicer, and Human Splicing
Finder algorithms implemented in the Alamut Visual soft-
ware (Interactive Biosoftware, Rouen, France). Although
family member genotypic information was unavailable for
most VUS, familial segregation analysis was performed
wherever possible using a recently described method [15].
By reviewing all available disease and literature databases,
including the BIC, ClinVar, Sharing Clinical Reports Project
(SCRP), PubMed, and the Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/), functional and database data
were evaluated and utilized when sufficient information was
available. 
5. Structural modeling
To evaluate the structural impact of the BRCA p.Leu-
1780Pro mutation, a crystal structure of the BRCA1 BRCT 
repeats bound to a phosphorylated BACH1 peptide (1T29)
was retrieved from the RCSB Protein Data Bank, and the 
location of the variant was modeled with the PyMOL soft-
ware (Schrödinger, New York, NY). Sidechain rotamer
analysis was performed using the KiNG software (Kine-
mage, Next Generation) [16]. 
6. Simulation of 95% CIs of ORs in cases and controls
To estimate adequate numbers needed for statistical analy-
sis, we calculated the OR and 95% CI by simulating the total
number of cases and controls from 100 to 10,000, a variant
frequency in cases from 0.1% to 10%, and the number of con-
trol individuals carrying the same variant from 0 to 5. 
Results
1. Characterization of variants for reclassification
We revisited 144 variants (69 variants of BRCA1 and 75
variants of BRCA2), including 58 variants reported to be dis-
ease-causing mutations and 86 reported to be VUS in the
original 3-tier classification. All disease-causing mutations
were null variants and included 24 nonsense, 26 frameshift,
and eight splice-site mutations. The VUS included 64 mis-
sense, 14 synonymous, and eight intronic variants. Further-
more, we compared our cohort to an additional cohort of 715
Korean patients with breast cancer [12] that included 23 mis-
sense VUS.
2. Population data analysis
We classified two BRCA2 variations, p.Ile3412Val and
p.Ile2490Thr, to meet benign criterion weighted as stand-
alone (BA1) because the allele frequencies exceeded 5% in
ExAC, AFR, and AMR populations. Because the incidence of
HBOC is estimated to be between 1 in 400 and 1 in 800 [17],
we defined a minor allele frequency (MAF) > 0.1% as too
high for the disorder, and therefore classified it as BS1 
(benign criterion weighted as strong-1; allele frequency is
greater than expected for disorder). This is still a conservative
measure considering that many different BRCA1/2 mutations
have been reported, most of which are not highly prevalent
mutations except for those occurring within the Ashkenazi
Jewish population  [17]. Using MAFs calculated from six dif-
ferent ExAC populations, we could classify 27 variants as
BS1. Using MAFs from 1,314 Korean exomes, we identified
an additional nine out of 36 variants that we classified as BS1.
We found that ORs were falsely elevated when we used
ExAC data for control populations. For example, use of the
ExAC NFE data resulted in the lower limits of the 95% CI
being 1.0 for most variants (Fig. 1, S1 Table). Even when the
ExAC EAS data was used, the ORs of some variants, includ-
ing BRCA1 p.Ser1577Pro, BRCA2 p.Thr582Pro, and BRCA2
p.Asp1618Glu, were overinflated. Using Korean data, the
false positives could be excluded, and six variants could then
1014 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2017;49(4):1012-1021
BRCA2 I2490T
BRCA2 I3412V
BRCA1 Y856H
BRCA2 R18H
BRCA2 K2729N
BRCA1 F1662S
BRCA1 M1628T
BRCA1 P1150S
BRCA1 L52F
BRCA2 C315S
BRCA2 E425=
BRCA1 Q1604=
BRCA2 G2508S
BRCA2 S2697N
BRCA1 K1690Q
BRCA2 N830=
BRCA2 V2109I
BRCA1 T1449=
BRCA2 D1864N
BRCA1 A1474=
BRCA2 V821I
BRCA2 A2351G
BRCA1 V271M
BRCA2 K322Q
BRCA2 L709=
BRCA2 I1929V
BRCA1 G275D
BRCA2 S1733=
BRCA2 N2436I
BRCA1 S265=
BRCA2 L2396=
BRCA1 N824H
BRCA2 S1004N
BRCA2 C1348Y
BRCA2 L1687R
BRCA2 Y2884C
BRCA2 P3039L
BRCA2 L3135V
BRCA2 G2044V
BRCA2 D1990A
BRCA2 V2166L
BRCA2 M784V
BRCA2 D1618E
BRCA1 S1577P
BRCA2 T582P
BRCA2 c.9649–19G>A
BRCA2 A406A
BRCA1 c.4484+14A>G
BRCA1 c.548–15G>A
BRCA1 c.671–8A>G
BRCA2 P1947=
BRCA1 P1020=
BRCA1 S1217C
BRCA1 S1386=
BRCA2 S791=
BRCA1 G401E
BRCA1 D96E
BRCA1 P1106S
BRCA1 M128Th
BRCA1 V1791E
BRCA1 c.594–15G>A
BRCA1 c.547+14delG
BRCA2 S3397F
BRCA2 D991N
BRCA2 K1183R
BRCA2 N1666T
BRCA2 A2351P
BRCA2 G2569D
BRCA2 A2683P
BRCA2 c.9501+6G>A
BRCA1 E1576Q
BRCA1 C644S
BRCA2 c.317–10A>G
BRCA2 N2781S
BRCA2 V3078F
BRCA2 K1440N
BRCA2 K2982Q
BRCA1 N112Y
BRCA2 T2722I
BRCA2 I3103M
BRCA1 Y130*
BRCA1 K608fs*
BRCA1 c.213–1G>A
BRCA1 c.302–2A>C
BRCA1 L1365fs*
BRCA1 T1376fs*
BRCA1 Y1429fs*
BRCA1 Q1756fs*
BRCA1 Q430*
BRCA1 c.5075–2A>G
BRCA1 c.5194–2A>G
BRCA1 K505*
BRCA1 L611*
BRCA1 N1272*
BRCA1 c.4485–2A>G
BRCA1 L1418*
BRCA2 S1900*
BRCA2 S2143*
BRCA2 S2670*
BRCA2 c.516+1G>A 
BRCA2 D1864fs*
BRCA2 F2457fs*
BRCA2 G267fs*
BRCA2 c.8488–1G>A
BRCA2 T3085Qfs*
BRCA2 c.9254_9256+11del
BRCA2 V159M
BRCA1 E1114*
BRCA1 N909I
BRCA1 G1077Afs*
BRCA1 P1099fs*
BRCA1 T1677fs*
BRCA1 K467*
BRCA1 Q491*
BRCA1 Q1299*
BRCA1 S1374*
BRCA1 R1443*
BRCA1 C64R
BRCA1 E1754*
BRCA1 W1815*
BRCA2 S599*
BRCA2 Y792*
BRCA2 S2201fs*
BRCA2 I1859Kfs*
BRCA2 N2146Tfs*
BRCA2 D252fs*
BRCA2  I2675V
BRCA1 V340fs*
BRCA1 K812fs*
BRCA1 G1348fs*
BRCA1 L785*
BRCA1 W1837R
BRCA2 K437fs*
BRCA2 T933Rfs*
BRCA2 S1248fs*
BRCA1 E1694*
BRCA2 Q3026*
BRCA2 A938fs*
BRCA1 V1833Sfs*
BRCA1 S308fs*
BRC1 K1780P
BRCA2 K467*
BRCA2 R2494*
BRCA1 E1210fs*
10
0 1
10
,0
00
0.
01
0.
00
01
Be
ni
gn
Lik
el
y b
en
ig
n 
Un
ce
rta
in
 si
gn
ifi
ca
nc
e
Lik
el
y p
at
ho
ge
ni
c
Pa
th
og
en
ic
vs. Korean exome
Odds ratio
10
0 1
10
,0
00
0.
01
0.
00
01
vs. ExAc EAS
Odds ratio
10
0 1
10
,0
00
0.
01
0.
00
01
vs. ExAc NFE
Odds ratio
Fi
g. 
1. 
 O
dd
 ra
tio
s (
OR
s) 
ca
lcu
lat
ion
s u
sin
g d
iff
ere
nt
 po
pu
lat
ion
 da
ta.
 C
om
pa
ris
on
 of
 ca
se
s w
ith
 no
n-
Fin
nis
h E
ur
op
ea
ns
 (N
FE
) fr
om
 Ex
om
e A
gg
reg
ati
on
 C
on
so
rti
um
(E
xA
C)
 re
su
lts
 in
 ov
er
in
fla
tio
n 
of
 O
Rs
. O
R 
in
fla
tio
n 
wa
s s
til
l n
ot
ed
 fo
r s
om
e b
en
ign
 v
ar
ian
ts 
us
in
g E
as
t A
sia
n 
(E
AS
) p
op
ul
ati
on
 d
ata
. V
ar
ian
ts 
we
re
 cl
as
sif
ied
 
ac
co
rd
in
g t
o t
he
 A
m
er
ica
n C
oll
eg
e o
f M
ed
ica
l G
en
eti
cs 
an
d G
en
om
ics
 (A
CM
G)
 st
an
da
rd
s a
nd
 gu
id
eli
ne
s. 
Ro
un
d d
ot
s i
nd
ica
te 
OR
 an
d a
 co
nt
in
uo
us
 lin
e t
hr
ou
gh
th
e d
ot
 in
di
ca
tes
 a 
95
% 
co
nf
id
en
ce
 in
ter
va
l.
VOLUME 49 NUMBER 4 October 2017  1015
Ji Soo Park, Ethnic Controls for Analyzing BRCA1/2 Variants
be classified as PS4 (pathogenic criterion weighted as strong-
4; the prevalence of the variant in affected individuals com-
pared with the prevalence in controls). Interestingly, among
this group, we identified a missense variant, BRCA1 c.5339T-
>C (p.Leu1780Pro; rs80357474), which was a previously 
reported VUS. However, in our analysis, this variant had a sig-
nificantly high OR (41.2; 95% CI, 2.4 to 699.5). Apart from these
six variants, 88 (including 52 null variants) were absent from
the population database and were classified as PM2 (patho-
genic criterion weighted as moderate-2; absent from controls).
3. Computational, functional, familial, and database data
analysis
Among 64 missense variants, 18 were predicted to have no
effect on the gene product according to all five computational
algorithms and were classified as BP4 (benign criterion
weighted as supporting-4; multiple lines of computational
evidence suggest no impact on gene or gene product). In con-
trast, 13 variants were predicted as deleterious using all 
algorithms and were classified as PP3 (pathogenic criterion
weighted as supporting-3; multiple lines of computational
A
B
BACH1
L1780
Fig. 2. Structural modeling for BRCA1 p.Leu1780Pro. (A) The p.Leu1780Pro residue is not located on substrate-binding sites
and a mutation at this site is not predicted to directly affect interaction with substrates. (B) Rotamer analysis shows that a
substitution of the leucine residue for a proline residue with a bulky aromatic side chain causes a clash with adjacent amino
acids and disrupts the -helical structure that maintains the BRCT domain.
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of cases and controls required for the lower limit of a 95% confidence interval to exceed 1.0 varies according to the variant
frequency in cases and variant observation in controls.
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evidence support a deleterious effect on gene or gene prod-
uct). None of the 14 synonymous variants were predicted to
affect splicing and were classified as BP7 (benign criterion
weighted as supporting-7; a synonymous variant for which
splicing prediction algorithms predict no impact on the splice
consensus sequence nor the creation of a new splice site and
the nucleotide is not highly conserved). Seven missense vari-
ants were reported as deleterious by previous functional
studies and classified here as PS3 (pathogenic criterion
weighted as strong-3; well-established in vitro or in vivo func-
tional studies supportive of a damaging effect on the gene or
gene product). Familial segregation and de novo data could
not be obtained for most patients. None of the investigated
families fulfilled the criteria for evidence [15] due to the small
number of family members who were genotyped.
4. ACMG classification
All of the 58 null variants that were previously classified
as disease-causing mutations were classified as P or LP, 
except for BRCA1 p.Tyr130Ter (rs80356888), which was pres-
ent in one individual among 3,933 ExAC EAS controls and
therefore could not be classified as PM2. Six among 86 vari-
ants (7.0%) previously reported as VUS were reclassified as
P or LP, 45 (52.3%) were reclassified into B or LB, and the 
remaining 35 (40.7%) remained classified as VUS (S2 Table).
Among the seven high-frequency VUS (> 1% of all patients),
only BRCA1 p.Leu1780Pro was classified as P, while the 
remaining ones were classified as B or BP (S3 Table). In total,
126 of the 745 patients (16.9%) with features of HBOC har-
bored variants (63 types) that were classified as P or LP 
according to the ACMG classification.
5. BRCA1 p.Leu1780Pro is a founder mutation in Koreans
BRCA1 p.Leu1780Pro, a missense VUS remarkably enri-
ched in patients over population controls, was classified as
P using multiple evidence categories, including PS4, PS3, and
PP3. This variant was observed in 11 of our 745 patients
(1.5%), which was equal to 8.7% of the 126 patients with P or
LP variants. All five algorithms predicted this variant as dele-
terious. Leu1780 is located at the C-terminal end of the BRCT 
domain, an area in which other pathogenic missense variants
have been reported [18,19], but it does not appear to be 
directly involved in substrate binding. The replacement of
leucine with proline, which has a bulky aromatic side chain,
is predicted to cause a side-chain clash with adjacent amino
acids and disrupt the -helical structure of the BRCT domain
(Fig. 2). 
The clinicopathological features of 11 patients with the
BRCA1 p.Leu1780Pro mutation are presented in Table 1.
Among them, 10 were diagnosed with breast cancer, and the
median age at the time of first diagnosis was 37 (range, 34 to
53). Most of these cases (8 of 10) were triple-negative breast
cancer. Three patients were diagnosed with epithelial ovar-
ian cancer, two of which had both breast cancer and ovarian
cancer. Additionally, two patients had bilateral breast can-
cers. Six of the 11 patients had at least one first-degree rela-
tive with breast cancer and/or ovarian cancer (Table 1, 
S4 Fig.). Although these findings were very typical of HBOC,
we did not classify them as PP4 because of the locus hetero-
geneity that exists in breast and ovarian cancers [9]. Finally,
patients carrying the BRCA1 p.Leu1780Pro mutation lacked
any other pathogenic BRCA1 or BRCA2 mutations.
6. Simulation to determine the optimal numbers of subjects
for OR calculations
Because we could effectively obtain evidence and discover
pathogenic variants using statistical approaches, we explored
how many cases and controls would be needed to reach sta-
tistical significance. For a variant, increasing the number of
controls can increase the OR and statistical significance, and
the minimum number of controls needed varies depending
on the frequency of the variant in cases and in controls. If a
variant is present at a frequency of 1% (10 in 1,000 cases) and
absent from controls, at least 820 controls are needed for the
lower limit of a 95% CI to exceed 1.0 (Fig. 3A). Moreover, 
although more than 4,000 controls are needed for a variant
existing in 0.2% of cases and 0% of controls, 500 cases are suf-
ficient for a statistically valuable calculation, and increasing
the number of cases provides little additional advantage.
However, more cases and controls are needed if one or more
individuals with the variant are present in control popula-
tions (Fig. 2B). For variants existing at a high proportion in
cases (e.g., > 1%), small numbers of cases and controls are
sufficient to reach statistical significance (S5 Fig.).
Discussion
The ACMG guidelines were developed to improve and
standardize classification of potentially pathogenic genetic
variants by defining 28 criteria. Nevertheless, ambiguity still
exists in applying certain criteria; therefore, efforts are ongo-
ing to increase the clarity of criteria and improve concor-
dance in variant interpretation among different laboratories
and geneticists [9]. Using general population data may be
one of the most powerful tools for selecting pathogenic vari-
ants and excluding benign polymorphisms in an objective
manner. However, our results show that caution should be
exercised when population data from different racial or eth-
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nic groups are used in analyses. Korea is located between
China and Japan; therefore, the genetic characteristics of 
Koreans are considered to be similar to those of Chinese and
Japanese people. However, when we used the ExAC EAS
data in our analysis, which is mainly composed of Chinese
and Japanese individuals, we calculated misleadingly high
ORs for some variants. Because there are likely Korean-spe-
cific polymorphisms, using relevant Korean population con-
trols is the best way to avoid inaccurate conclusions. 
Additionally, our simulation raises issues and concerns 
regarding the optimal number of population controls. This
varies depending on the frequency of the variant in cases.
For rare pathogenic variants, a large number of controls is
needed. For example, the BRCA1 p.Leu1780Pro variant that
was present in 1.5% of cases, was marginally significant (OR,
19.5; 95% CI, 1.1 to 331.5) when 622 Korean controls from
KRGDB were used. Considering that p.Leu1780Pro was the
second most prevalent mutation in our series, it is likely that
tens of thousands of relevant controls are needed for most
other rare variants.
Classifying VUS into pathogenic or neutral variants is a
challenge for clinicians evaluating the BRCA1 or BRCA2
mutation status of patients with features of HBOC. Efforts
are being made to reclassify VUS and reduce the rate at
which they are reported. For example, Myriad Genetic Lab-
oratories reduced the VUS rate to 2.1% using their exclusive
database [20,21]. Open-access databases and research con-
sortia, including ClinVar, the BIC and the Evidence-based
Network for the Interpretation of Germline Mutant Alleles
(ENIGMA) also play important roles in the interpretation of
VUS. Nonetheless, these databases primarily consist of 
patients from Western countries, making it difficult to use
these populations to interpret the clinical significance of vari-
ants found in Asian or other ethnic populations. 
The BRCA1 p.Leu1780Pro variant appears to be specific to
Koreans. Only one Asian case (detailed ethnicity unknown)
with BRCA1 p.Leu1780Pro was listed in the BIC, and this was
submitted by Myriad Genetics Laboratories and graded as
VUS. ClinVar and SCRP also list three submissions with a
VUS interpretation. Interestingly, other reports of this variant
are restricted to studies using Korean cohorts, all of which
classify the variant as VUS [12,22-24]. In our study, this vari-
ant was found in 11 cases and was the second most common
mutation after BRCA1 c.3627dupA (12 cases). BRCA1 Leu-
1780 is located at the 1-helix of the C-terminal end of two
BRCT domains (amino acids 1,646-1,859), which are critical
for DNA repair activity. In response to DNA damage, the
BRCT domain binds to phosphorylated proteins that are 
essential for the DNA damage response [25]. Pathogenic mis-
sense variants reported to date have mainly been located at
the BRCT domain [18,19]. Lee et al. [26] conducted a compre-
hensive functional analysis of missense variants in the BRCT
domain using multiple assays, including proteolysis tests, to
measure protein folding stability, phosphopeptide binding
assays to measure binding activity and specificity of peptide
interaction, and transcriptional assays to measure transcrip-
tional activation activity. They found that the BRCA1 p.Leu-
1780Pro mutation causes adverse effects on cells in the above
assays. 
We observed that the clinicopathological features of 
patients carrying BRCA1 p.Leu1780Pro were typical of
HBOC (S6 Table) [17]. Although all enrolled cases were sus-
pected HBOC cases, the clinical features of patients with
BRCA1 p.Leu1780Pro were remarkable among the enrolled
subjects. For familial investigation, information regarding the
parents’ history and genotype was unavailable for most fam-
ilies, in part because of the influence of the Korean War, fol-
lowed by the division of territory, and infrequent visits to
clinics until the mid-20th century. Issues related to incom-
plete penetrance over a lifetime, inclusion of pathogenic vari-
ants in the general population controls, and missense vari-
ants with hypomorphic characteristics associated with mod-
erate to low risk likely remain [27].
In conclusion, we applied the ACMG guidelines and 
reclassified variants in BRCA1/2 in Korean patients with fea-
tures of HBOC. We found that East Asian control popula-
tions are inappropriate for accurate OR calculations, and the
use of relevant Korean controls helped us to identify patho-
genic variants, including one founder mutation, BRCA1
p.Leu1780Pro. Our simulation demonstrated that a sufficient
number of controls is needed for rare variants to be statisti-
cally evaluated (for instance, more than 820 relevant ethnic
controls for a variant existing in 1% of cases); therefore, large
genome projects for individual ethnic groups will be needed
in the future for more accurate interpretation of genetic vari-
ants.
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